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Background
Lipopolysaccharide (LPS) and peptidoglycan are microbial
products recognized by Toll-like receptor-4 (TLR4) and
nucleotide-binding oligomerization domain 1 (NOD1) and
NOD2, respectively. LPS has been found to cause beha-
vioural alterations indicative of sickness and depressed
mood. The effect of peptidoglycan on exploratory and
affective behaviour has not yet been explored, although it
has been reported that it promotes sleep and anorexia.
Since NOD1 and NOD2 are activated by two different
peptidoglycan components, MurNAc-L-Ala-g-D-Glu-
meso-diaminopimelic acid (M-TriDAP) and muramyl
dipeptide (MDP), respectively, the effects of both com-
pounds, alone and in combination with LPS, on explora-
tory and affective behaviour were investigated.
Methods
Female C57BL/6 mice received intraperitoneal injections
of M-TriDAP (100 µg/mouse), MDP (10 mg/kg) or sterile
saline (0.9% NaCl) and additional injections of LPS (0.83
mg/kg) or sterile saline 4 hours after the first injection.
The weight of the animals was monitored throughout the
study. Exploratory and anxiety-like behaviour was evalu-
ated with the elevated plus-maze test (EPM) 1 day after
treatment, while depression-related (stress coping) beha-
viour was assessed with the forced swim test (FST) 1 week
after treatment.
Results
Mice receiving sterile saline plus LPS, M-TriDAP plus LPS
and MDP plus LPS, respectively, lost body weight by 12%
during the first day after treatment, which was reversed 1
week after treatment. When given alone, M-TriDAP and
MDP failed to change the body weight. Likewise, M-Tri-
DAP and MDP alone did not alter behaviour on the EPM
as tested 1 day after treatment. LPS alone decreased
exploratory behaviour in the EPM as displayed by a non-
significant reduction of the total travelling distance and
number of arm entries. When given in combination with
LPS, especially MDP enhanced the effect of LPS. Specifi-
cally, the decrease of the total travelling distance and the
total number of arm entries reached statistical significance.
When tested in the FST, the animals tended to exhibit
increased immobility and decreased activity (swimming
and climbing), an effect that was again most pronounced
in the MDP plus LPS group. However, this effect was not
statistically significant.
Conclusions
The loss of body weight and decrease in exploratory
behaviour following administration of bacterial immune
stimulants reflect sickness behaviour associated with
infection. The present results reveal that MDP, a NOD2
agonist, enhances the sickness behaviour caused by LPS.
This observation indicates that the brain response to
peripheral immune activation depends on both TLR4
and NOD2.
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